Registry of Cell Therapy in Non-Ischemic Dilated Cardiomyopathy
ConditionCardiomyopathy, Dilated
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorUniversity Medical Centre Ljubljana
About this trial
Although several studies have demonstrated beneficial effects of stem cell therapy in patients with non-ischemic dilated cardiomyopathy, the long term benefits and predictors of response to therapy remain undefined. The aim of this registry is to pool long-term clinical data in patients with non-ischemic dilated cardiomyopathy undergoing autologous cell therapy in an attempt to better define predictors of response to such treatment.
Eligibility criteria
Qualifiers
Patient inclusion criteria consisted of the following: age 18-65 years old, diagnosis of DCM according to the European Society of Cardiology position statement (9), optimal medical management for at least 6 months, left ventricular ejection fraction (LVEF) <40%, and New York Heart Association functional Class III on stable medical therapy for at least 3 months before referral.
Disqualifiers
Patients with acute multi-organ failure or a history of hematologic neoplasms were not included.
Trial design
Treatments tested in this trial
- Autologous stem cell therapy
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov